Novo is also launching higher-dose formulations, developing companion therapies, and pursuing additional indications (cardiovascular prevention, kidney disease)
That said, a real-world analysis by Prime Therapeutics and Magellan Rx looked at integrated pharmacy and medical claims data from 16 million commercially insured members and found that a whopping 68% had stopped taking their GLP-1s after just one year
While the FDA approves certain doses, that is based on the average results of clinical trials, but you as an individual are unique
With Paloma, youre not just treating symptomsyoure building a healthier future
3163 involves claims that Ozempic and other GLP-1 medications caused non-arteritic anterior ischemic optic neuropathy, or NAION, a serious optic nerve injury that can cause sudden and permanent vision loss
Of note, in the STEP 1 extension trial, participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide, and improvements in blood pressure, cholesterol, and glucose largely reversed
